default author photo

John D. Lewis

University of Alberta - Department of Oncology

SCHOLARLY PAPERS

3

DOWNLOADS

432

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Safe and Effective Delivery of Nucleic Acids Using Proteolipid Vehicles Formulated with Fusion-Associated Small Transmembrane Proteins

Number of pages: 66 Posted: 07 Oct 2022
University of Alberta - Department of Oncology, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, University of Alberta - Department of Oncology, OncoSenX, Dalhousie University - Department of Microbiology & Immunology, University of Alberta - Department of Oncology, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, Entos Pharmaceuticals, Oisin Biotechnologies, Entos Pharmaceuticals, Entos Pharmaceuticals, Oisin Biotechnologies, Dalhousie University - Department of Microbiology & Immunology, Entos Pharmaceuticals and University of Alberta - Department of Oncology
Downloads 195 (391,686)

Abstract:

Loading...

Encapsulation, FAST proteins, FAST-PLV, Gene therapy, Nucleic acid delivery, proteolipid vehicle, PLV, p14endo15, Follistatin

2.

Predicting Clinically Significant Prostate Cancer with or Without Digital Rectal Exam and MRI Data Using Claritydx Prostate Models

Number of pages: 32 Posted: 04 Sep 2024
Nanostics Inc, University of Alberta, University of Calgary, Nanostics Inc, University of California, Los Angeles (UCLA) - UCLA Health System, Johns Hopkins University, Johns Hopkins University, Charles University, Charles University, Charles University, Nanostics Inc, University of Toronto, Nanostics Inc, Nanostics Inc, Nanostics Inc and University of Alberta - Department of Oncology
Downloads 119 (600,462)

Abstract:

Loading...

clinically significant prostate cancer, Diagnostic Tests Routine, machine learning, prostatic neoplasms, risk score

3.

Immunogenicity of a SARS-CoV-2 DNA Vaccine Formulated With the Fusion-Associated Small Transmembrane Protein Proteolipid Vehicle Delivery System

Number of pages: 49 Posted: 01 Nov 2022
Entos Pharmaceuticals, OncoSenX, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, University of Alberta - Department of Oncology, Dalhousie University - Department of Microbiology & Immunology, Entos Pharmaceuticals, Entos Pharmaceuticals, Oisin Biotechnologies, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, Entos Pharmaceuticals, University of Alberta - Department of Oncology, Entos Pharmaceuticals, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, Aegis Life, Entos Pharmaceuticals, Entos Pharmaceuticals, Aegis Life, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, Dalhousie University - Department of Microbiology & Immunology, University of Saskatchewan - Vaccine and Infectious Disease Organization, Aegis Life, University of Saskatchewan - Vaccine and Infectious Disease Organization, Dalhousie University - Department of Microbiology & Immunology and University of Alberta - Department of Oncology
Downloads 118 (608,822)

Abstract:

Loading...

CD8+ T cells, cytotoxic T lymphocytes, FAST protein, genetic adjuvants, neutralizing antibodies, plasmid DNA vaccine, proteolipid vehicle, PLV, SARS-CoV-2, Spike protein